Company Profile: Zelda Therapeutics Ltd (ASX: ZLD) is a cannabis group that works on a varied range of formulations based on cannabinoid for treating several medical conditions. The group has partnerships with well-known names such as Aunt Zelda’s, CannPal, and Curtin University to name a few. The Company is working on 2 approaches that involve a human clinical trial program for conditions such as insomnia, autism and eczema; and a pre-clinical research program for impact of cannabinoids in breast, brain and pancreatic cancer. The new approach being worked upon includes potential for cannabinoids to treat diabetes-associated cognitive decline. The group operates in Australia, the United States and Chile.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.
Click here for your FREE Report